1024免费一级欧美片在线观看_久久免费精品视频互動交流_国国产无套粉嫩白浆在线_饥渴难耐的浪荡艳妇_亚洲国产日韩一区在线_欧美激情性爱吧_精品人妻少妇av嫩草_嗯啊不要视频_另类欧美亚洲综合_网友自拍亚洲无码另类

杭州昊鑫生物科技股份有限公司
網(wǎng)站標(biāo)題
搜索

取消

清空記錄

歷史記錄

清空記錄

歷史記錄

清空記錄

歷史記錄

杭州昊鑫生物科技股份有限公司
    當(dāng)前位置:
  • 首頁>
  • 產(chǎn)品中心>
  • MCE>
  • Deferoxamine...

產(chǎn)品中心

Deferoxamine mesylate (甲磺酸去鐵胺)

分享到微信

×
Deferoxamine mesylate是一種鐵螯合劑,可將游離鐵與穩(wěn)定的復(fù)合物結(jié)合,防止其發(fā)生化學(xué)反應(yīng)。
貨號(hào):HY-B0988
CAS:138-14-7
參數(shù)品牌:MCE
產(chǎn)品參數(shù)
品牌:MCE
型號(hào):HY-B0988
起訂量:1
規(guī)格::100mg
價(jià)格::¥500
我知道了
在線客服
產(chǎn)品詳情

生物活性

Deferoxamine mesylate is an iron chelator that binds free iron in a stable complex, preventing it from engaging in chemical reactions.


體外研究(In Vitro)

Deferoxamine treatment significantly increases HIF-1α binding under all culture conditions, including hypoxic and high-glucose. The mechanism of deferoxamine is through improving HIF-1α biological function through scavenging oxygen free radicals[1]. Deferoxamine (5 μM) has significant effect on the tumor-associated stromal cells cellular multiplication, and cells die at day 7 after exposure to 50 μM and 100 μM deferoxamine. Deferoxamine (5 μM-100 μM) inhibits the proliferation of BMMSCs, and induces apoptosis of MSCs in a dose-dependent manner. Deferoxamine influences the expression of adhesion proteins on MSCs[3]. Deferoxamine (30, 60, 120?μM) shows lower expression of HIF-1α in a concentration dependent way in AdMSCs[4].


體內(nèi)研究(In Vivo)

Deferoxamine (100 mg/kg, i.p.) lowers the mortality rate of subarachnoid hemorrhage (SAH) rat. Deferoxamine (100 mg/kg, i.p.) attenuates Evan’s blue extravasation in cortex, ameliorates the tight junction detachment and preserves the integrity of the base membrane examined in electron microscope at day 3 after SAH. Deferoxamine attenuates degradation of BBB proteins after SAH and significantly reduces ferritin expression at day 3 in the cortex, and improves neurologic behavior and cognitive deficits after experimental[1]. Ten μL of 1 mM deferoxamine-treated wounds display significantly accelerated healing from day 7 onward and heal significantly faster than control-treated wounds in diabetic mice. Deferoxamine-treated wounds and dimethyloxalylglycine-treated wounds heal significantly faster than control-treated wounds in aged mice[2]. In deferoxamine (10 mg/mL)-treated TG mice, there is a decrease in both soluble and insoluble Aβ40 and Aβ42. Both pGSK3β and β-catenin are significantly increased by approximately 50% in the deferoxamine-treated mice[5].


分子量:656.79


Formula:C26H52N6O11S


CAS 號(hào):138-14-7


中文名稱:甲磺酸去鐵胺;去鐵胺甲磺酸酯;甲磺酸去鐵敏;甲磺酸除鐵靈


儲(chǔ)存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)


溶解性數(shù)據(jù)

In Vitro: 

H2O : 250 mg/mL (380.64 mM; Need ultrasonic)

配制儲(chǔ)備液
濃度溶劑體積質(zhì)量1 mg5 mg10 mg
1 mM1.5226 mL7.6128 mL15.2256 mL
5 mM0.3045 mL1.5226 mL3.0451 mL
10 mM0.1523 mL0.7613 mL1.5226 mL
*

請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 儲(chǔ)存時(shí),請(qǐng)?jiān)?6 個(gè)月內(nèi)使用,-20°C 儲(chǔ)存時(shí),請(qǐng)?jiān)?1 個(gè)月內(nèi)使用。

In Vivo:

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液,再依次添加助溶劑:

——為保證實(shí)驗(yàn)結(jié)果的可靠性,澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的工作液,建議您現(xiàn)用現(xiàn)配,當(dāng)天使用; 以下溶劑前顯示的百
分比是指該溶劑在您配制終溶液中的體積占比;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的方式助溶

  • 1.


    請(qǐng)依序添加每種溶劑: PBS

    Solubility: 5.56 mg/mL (8.47 mM); Clear solution; Need ultrasonic



參考文獻(xiàn)

[1]. Li Y, et al. Effects of deferoxamine on blood-brain barrier disruption after subarachnoid hemorrhage. PLoS One. 2017 Mar 1;12(3):e0172784

[2]. Duscher D, et al. Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. Plast Reconstr Surg. 2017 Mar;139(3):695e-706e

[3]. Wang G, et al. In vitro assessment of deferoxamine on mesenchymal stromal cells from tumor and bone marrow. Environ Toxicol Pharmacol. 2017 Jan;49:58-64

[4]. Wahl EA, et al. VEGF released by deferoxamine preconditioned mesenchymal stem cells seeded on collagen-GAG substrates enhances neovascularization. Sci Rep. 2016 Nov 10;6:36879

[5]. Fine JM, et al. Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation. Neurosci Lett. 2015 Jan 1;584:362-7

Deferoxamine mesylate (甲磺酸去鐵胺)
Deferoxamine mesylate (甲磺酸去鐵胺)

Deferoxamine mesylate (甲磺酸去鐵胺)

分享到微信

×
Deferoxamine mesylate是一種鐵螯合劑,可將游離鐵與穩(wěn)定的復(fù)合物結(jié)合,防止其發(fā)生化學(xué)反應(yīng)。
貨號(hào):HY-B0988
CAS:138-14-7
品牌:MCE
型號(hào):HY-B0988
起訂量:1
規(guī)格::100mg
價(jià)格::¥500
15906629305
在線客服
產(chǎn)品詳情

生物活性

Deferoxamine mesylate is an iron chelator that binds free iron in a stable complex, preventing it from engaging in chemical reactions.


體外研究(In Vitro)

Deferoxamine treatment significantly increases HIF-1α binding under all culture conditions, including hypoxic and high-glucose. The mechanism of deferoxamine is through improving HIF-1α biological function through scavenging oxygen free radicals[1]. Deferoxamine (5 μM) has significant effect on the tumor-associated stromal cells cellular multiplication, and cells die at day 7 after exposure to 50 μM and 100 μM deferoxamine. Deferoxamine (5 μM-100 μM) inhibits the proliferation of BMMSCs, and induces apoptosis of MSCs in a dose-dependent manner. Deferoxamine influences the expression of adhesion proteins on MSCs[3]. Deferoxamine (30, 60, 120?μM) shows lower expression of HIF-1α in a concentration dependent way in AdMSCs[4].


體內(nèi)研究(In Vivo)

Deferoxamine (100 mg/kg, i.p.) lowers the mortality rate of subarachnoid hemorrhage (SAH) rat. Deferoxamine (100 mg/kg, i.p.) attenuates Evan’s blue extravasation in cortex, ameliorates the tight junction detachment and preserves the integrity of the base membrane examined in electron microscope at day 3 after SAH. Deferoxamine attenuates degradation of BBB proteins after SAH and significantly reduces ferritin expression at day 3 in the cortex, and improves neurologic behavior and cognitive deficits after experimental[1]. Ten μL of 1 mM deferoxamine-treated wounds display significantly accelerated healing from day 7 onward and heal significantly faster than control-treated wounds in diabetic mice. Deferoxamine-treated wounds and dimethyloxalylglycine-treated wounds heal significantly faster than control-treated wounds in aged mice[2]. In deferoxamine (10 mg/mL)-treated TG mice, there is a decrease in both soluble and insoluble Aβ40 and Aβ42. Both pGSK3β and β-catenin are significantly increased by approximately 50% in the deferoxamine-treated mice[5].


分子量:656.79


Formula:C26H52N6O11S


CAS 號(hào):138-14-7


中文名稱:甲磺酸去鐵胺;去鐵胺甲磺酸酯;甲磺酸去鐵敏;甲磺酸除鐵靈


儲(chǔ)存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)


溶解性數(shù)據(jù)

In Vitro: 

H2O : 250 mg/mL (380.64 mM; Need ultrasonic)

配制儲(chǔ)備液
濃度溶劑體積質(zhì)量1 mg5 mg10 mg
1 mM1.5226 mL7.6128 mL15.2256 mL
5 mM0.3045 mL1.5226 mL3.0451 mL
10 mM0.1523 mL0.7613 mL1.5226 mL
*

請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效
儲(chǔ)備液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 儲(chǔ)存時(shí),請(qǐng)?jiān)?6 個(gè)月內(nèi)使用,-20°C 儲(chǔ)存時(shí),請(qǐng)?jiān)?1 個(gè)月內(nèi)使用。

In Vivo:

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液,再依次添加助溶劑:

——為保證實(shí)驗(yàn)結(jié)果的可靠性,澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的工作液,建議您現(xiàn)用現(xiàn)配,當(dāng)天使用; 以下溶劑前顯示的百
分比是指該溶劑在您配制終溶液中的體積占比;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的方式助溶

  • 1.


    請(qǐng)依序添加每種溶劑: PBS

    Solubility: 5.56 mg/mL (8.47 mM); Clear solution; Need ultrasonic



參考文獻(xiàn)

[1]. Li Y, et al. Effects of deferoxamine on blood-brain barrier disruption after subarachnoid hemorrhage. PLoS One. 2017 Mar 1;12(3):e0172784

[2]. Duscher D, et al. Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. Plast Reconstr Surg. 2017 Mar;139(3):695e-706e

[3]. Wang G, et al. In vitro assessment of deferoxamine on mesenchymal stromal cells from tumor and bone marrow. Environ Toxicol Pharmacol. 2017 Jan;49:58-64

[4]. Wahl EA, et al. VEGF released by deferoxamine preconditioned mesenchymal stem cells seeded on collagen-GAG substrates enhances neovascularization. Sci Rep. 2016 Nov 10;6:36879

[5]. Fine JM, et al. Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation. Neurosci Lett. 2015 Jan 1;584:362-7

選擇區(qū)號(hào)